The meeting brought together more than 40 vaccine manufacturers from 17 developing countries, alongside global health organisations, regulators and financial institutions. Co-hosted by DCVMN, BJFPI, Sinovac, BioKangtai and Zhifei, the gathering was held under the theme, “Transforming Innovation into Immunisation”.
For Aspen, participation in this global forum reinforces the importance of collaboration in building sustainable vaccine manufacturing capacity and improving equitable access. It also creates an opportunity to ensure that the priorities and realities of African manufacturers remain part of international discussions on vaccine financing, development, production and delivery.
Advancing Africa’s voice
Stavros’ board role provides a platform to connect Southern Africa’s ambitions with the experience and partnerships of the wider vaccine manufacturing community. His participation reflects Aspen’s continued advocacy for stronger regional production, resilient supply chains and procurement approaches that support the long-term viability of African manufacturing.
The programme includes discussions on regional production, financing, and regulatory cooperation, including World Health Organisation prequalification. Delegates are also exploring the use of artificial intelligence in research, manufacturing, and supply chains, as well as ways to strengthen public confidence in vaccination.
By taking part in these conversations, Aspen is helping to build the partnerships needed to translate scientific progress into reliable access for communities. The Beijing meeting is a timely reminder that meaningful vaccine equity depends not only on innovation, but also on coordinated action, sustainable markets and the inclusion of manufacturers from developing countries.